Jana Ďuricová

Ms. Jana Ďuricová

avatar
Co-authors
avatar
Following
avatar
Followers

Research Focus & Metrics

Explore full metrics on Scilit

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2012 in Biomedical Papers
Verified
Journal Article
Open access
PDF file
NPNadežda Petejová
Nadežda Petejová
AMArnost Martinek
Arnost Martinek
JZJana Zahalkova
Jana Zahalkova
JĎJana Ďuricová
Jana Ďuricová
HBHana Brozmanova
Hana Brozmanova
Ivana KacirovaIvana Kacirova
Ivana Kacirova
Aims: To determine the extent of vancomycin removal and vancomycin pharmacokinetics in septic patients with AKI using daily hemodialysis with polysulphone high-flux and low-flux membrane. Methods: Five patients received 6 h daily dialysis with...
14 June 2017 in Biomedical Papers
Verified
Journal Article
Open access
PDF file
EVErika Hrudikova Vyskocilova
Erika Hrudikova Vyskocilova
MGMilan Grundmann
Milan Grundmann
JĎJana Ďuricová
Jana Ďuricová
Ivana KacirovaIvana Kacirova
Ivana Kacirova
Amiodarone is the most effective agent in the therapy of arrhythmias. However, the clinical effect of acute and chronic treatment is unclear and there are differences irrespective of comparable plasma/myocardial amiodarone and its metabolite desethylamiodarone concentations as well. Its unusual pharmacokinetics results in interindividual variation in plasma levels. The association between amiodarone and desethylamiodarone plasma levels and clinical efficacy is difficult to evaluate. This review was carried out to assess whether there is any objective correlation between amiodarone and desethylamiodarone plasma levels and the clinical effect. We summarized the results of relevant studies and clarified the relationship between plasma levels and effect vis á vis the pharmacokinetics and pharmacogenetics of this drug. Certain correlation was seen with oral amiodarone therapy, in others, plasma amiodarone levels were unrelated to therapeutic response and showed no correlation with changes in electrocardiogram or electrophysiological parametres. Several studies show that plasma concentration ranging between 0.5 and 2.5 mg/L appears to be the most effective, others demonstrate no difference between responders and non-responders. One way of interpreting plasma levels is to establish an individual patient´s effective concentration. Therapeutic drug monitoring can contribute to determining optimal concentration.
1 April 2014 in Biomedical Papers
Verified
Journal Article
Open access
PDF file
NPNadežda Petejová
Nadežda Petejová
AMArnost Martinek
Arnost Martinek
JZJana Zahalkova
Jana Zahalkova
JĎJana Ďuricová
Jana Ďuricová
HBHana Brozmannova
Hana Brozmannova
Ivana KacirovaIvana Kacirova
Ivana Kacirova
Aims: To assess the influence of continuous venovenous hemofiltration (CVVH) at a filtration rate of 45 mL/kg/h on vancomycin pharmacokinetics in critically ill septic patients with acute kidney injury (AKI). Methods: Seventeen adult s...
12 March 2009 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
MTMarko Toivanen
Marko Toivanen
ARAnu Ryynänen
Anu Ryynänen
SHSanna Huttunen
Sanna Huttunen
JĎJana Ďuricová
Jana Ďuricová
KRKaisu Riihinen
Kaisu Riihinen
CTCarina Tikkanen-Kaukanen
Carina Tikkanen-Kaukanen
14 January 2010 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
MTMarko Toivanen
Marko Toivanen
SHSanna Huttunen
Sanna Huttunen
JĎJana Ďuricová
Jana Ďuricová
PSPasi Soininen
Pasi Soininen
RLReino Laatikainen
Reino Laatikainen
CTCarina Tikkanen‐Kaukanen
Carina Tikkanen‐Kaukanen
1 April 2012 in Journal of Chemotherapy
Verified
Journal Article
Closed access
NPNadezda Petejova
Nadezda Petejova
JZJana Zahalkova
Jana Zahalkova
JĎJana Ďuricová
Jana Ďuricová
Ivana KacirovaIvana Kacirova
Ivana Kacirova
HBHana Brozmanova
Hana Brozmanova
AMArnost Martinek
Arnost Martinek
Current dosing recommendations for administration of gentamicin to septic patients with acute kidney injury (AKI) on continuous venovenous hemofiltration (CVVH) at a filtration rate of 45 ml/kg/h are missing. To describe gentamicin pharmacokinetics and to find an optimal dosing regimen in patients on CVVH. Seven adult patients were included. Patients received loading dose of 240 mg followed by application of maintenance dose every 24 hours. Maintenance dose was adjusted according to gentamicin C(max)/MIC ratio and drug levels simulation using a pharmacokinetic programme. Median total clearance (0.59-0.79 ml/min/kg) was similar to patients with normal renal function; median volume of distribution was higher than observed in non-septic patients (about 0.5 l/kg versus 0.25 l/kg). Patients with diuresis required an increase of gentamicin dose to reach C(max)/MIC ratio. Septic patients with AKI on CVVH (45 ml/kg/h) require a loading dose of 240 mg, followed by therapeutic drug monitoring to optimize maintenance dose.